Merck Stock Rises Above Peers on Pipeline Success

Merck (MRK) stock has outperformed its peers in the pharma industry over the past year, rising 83.8% compared to the S&P 500's 20.3%. The company's revenue growth rate of 4.6% is consistent with its historical average of 4.5%, but its stock price has diverged from its peers. Johnson & Johnson returned 53.7%, Eli Lilly 61.2%, and Pfizer matched the index at 19.6%.

The gap between Merck's performance and that of its peers can be attributed to the company's clinical readouts, which have been positive. The company has already launched several new products, including WINREVAIR for pulmonary arterial hypertension, which brought in $588 million globally in the second quarter of 2026. LIPFENDRA, an oral PCSK9 inhibitor, was also approved and shown to reduce LDL cholesterol by up to 60%.

Merck has been investing in its pipeline, including a $5.7 billion charge for Terns Pharmaceuticals' chronic myeloid leukemia candidate MK-4208. The company's guidance for 2026 revenue growth is modest at 2-4%, implying a flat second half compared to the trailing pace.